The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

COVID-19 Updates

CPRIT suspends first cycle of awards for FY21

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Cancer Prevention and Research Institute of Texas has suspended its first cycle of grant applications for fiscal year 2021 for Academic Research, Product Development Research and Prevention Program awards.

CPRIT is taking this action in response to the unexpected impact to the budget from the COVID-19 pandemic and a projected decrease in oil and gas revenues. CPRIT continues to evaluate releasing Requests for Applications for fiscal year 2021 and is committed to doing so if circumstances support it.

CPRIT has closed the FY 21.1 Academic Research Program RFAs listed below (originally due June 3). CPRIT will not accept applications responding to these RFAs and will withdraw any FY 21.1 applications already submitted.

Applications for the second cycle of fiscal year 2020 (FY 20.2) are undergoing peer review. CPRIT is not withdrawing the FY 20.2 applications and expects to announce awards in August or early fall.

  • RFA R-21.1 – RTA Research Training Awards

  • RFA R-21.1 – IIRA Individual Investigator Research Awards

  • RFA R-21.1 – IIRACCA Individual Investigator Research Awards for Cancer in Children and Adolescents

  • RFA R-21.1 – IIRACT Individual Investigator Research Awards for Clinical Translation

  • RFA R-21.1 – IIRACSBC Individual Investigator Research Awards for Computational Systems Biology of Cancer

  • RFA R-21.1 – IIRAP Individual Investigator Research Awards for Prevention and Early Detection

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
News Analysis

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ

Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs

Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.
By Jacquelyn Cobb and Sara Willa Ernst
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account